Oakio Set to Participate in Batimat Paris 2024 with Innovative WPC Solutions
12.7.2024 16:47:00 EEST | Business Wire | Press release
Oakio, a pioneer in eco-friendly and high-performance wood-plastic composite (WPC) products, will be participating in the Batimat Paris 2024 exhibition. The event will be held from September 30 to October 3 at Paris Expo Porte de Versailles, offering a premier platform for showcasing the latest advancements in the construction and building materials industry.
Batimat is a globally recognized event that brings together industry leaders, innovators, and professionals to explore the newest trends and technologies in construction. Oakio will be exhibiting at Booth H1-A066, where attendees can discover the full range of Oakio’s innovative products.
"We are delighted to be part of Batimat 2024 and to present our comprehensive range of sustainable building solutions," said Juno Zhong, Marketing Director at Oakio. "Our products are designed to meet the growing demand for environmentally responsible and high-performance materials in both residential and commercial projects."
The products showcased at the event include:
- WPC Decking: Combining the beauty of natural wood with the strength and low maintenance of composite materials, WPC decking is ideal for creating beautiful and long-lasting outdoor spaces.
- WPC Cladding: Offering exceptional durability, weather resistance, and aesthetic appeal, WPC cladding is perfect for enhancing the exterior of any building.
- WPC Fencing: Designed to provide privacy, security, and elegance, WPC fencing products come in a variety of styles to suit any landscape.
- WPC Railing: Perfect for balconies, staircases, and patios, WPC railing systems offer both safety and style.
- WPC Beam: Engineered for versatility and durability, WPC beam enhances both indoor and outdoor spaces with their attractive and sturdy design.
Visitors to Oakio’s booth will have the opportunity to experience these products firsthand through interactive demonstrations and expert consultations. The Oakio team will be on hand to provide insights and answer questions about how these innovative solutions can enhance various construction projects.
"Batimat 2024 is a significant event for us to connect with industry professionals and showcase the versatility and sustainability of our product range," added Juno Zhong. "We invite all attendees to visit our booth and explore how Oakio can help them achieve their building goals."
For those interested in the latest in sustainable building materials and design, Oakio’s booth at Batimat 2024 is a must-visit. For more information, please contact through Oakio official website: www.oakio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711972281/en/
Contacts
Juno Zhong
info@oakio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom